ACM
RGNX icon

Atika Capital Management’s Regenxbio RGNX Stock Holding History

Atika Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-60,000
Closed -$2M – 84
2017
Q4 		$2M Buy
60,000
+30,000
+100% +$904K 0.77% 53
2017
Q3 		$988K Buy
+30,000
New +$675K 0.28% 70

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Atika Capital Management's RGNX Position: Q1 2018 in Review

Atika Capital Management sold out of Regenxbio (RGNX) in Q1 2018, closing a stake of 60,000 shares — an estimated $2M sold.

Atika Capital Management first reported a position in RGNX in Q3 2017 and held it in 2 quarters. The position peaked at $2M in Q4 2017. 120 funds tracked by Wall St. Rank hold RGNX as of Q1 2018.

  • Atika Capital Management reported no remaining Regenxbio position as of Q1 2018 after selling out during the quarter.
  • Atika Capital Management sold 60,000 Regenxbio shares in Q1 2018, an estimated $2M.
  • Atika Capital Management first reported a position in Regenxbio in Q3 2017 and held it in 2 quarters.
  • Atika Capital Management's Regenxbio position peaked at $2M in Q4 2017.
  • 120 funds tracked by Wall St. Rank held Regenxbio as of Q1 2018.

Based on Atika Capital Management's 13F filing for Q1 2018, filed 15 May 2018.